Improvement of rat lung structure and function after preservation with celsior.
Ischemia/reperfusion-induced increase in pulmonary microvascular permeability was shown to be reduced after preservation with Celsior. We investigated reimplantation-induced lung injury in isolated, reperfused rat lungs after preservation via the pulmonary artery with Celsior, Celsior + prostacyclin, and reduced-potassium (40 mmol) Euro-Collins solution (40 ml/kg/body wt each) followed by 2 h of cold ischemia. Arterial and veneous oxygen tensions were recorded during 50 min of in vitro reperfusion after which the lungs (10 right lungs per experimental group) were fixed by vascular perfusion. The tissue was further processed for microscopy, and histological changes were quantified stereologically. Lung preservation with Celsior resulted in a significantly higher volume of air-filled alveolar space with a large proportion of widely distended alveoli compared with the other groups. In the Euro-Collins group the fraction of atelectatic alveoli exceeded that observed in Celsior-preserved lungs. In accordance, the difference between arterial and venous oxygen tensions was significant among Euro-Collins- and Celsior-protected lungs, with improved oxygenation values in the Celsior group. In contrast, addition of prostacyclin to Celsior treatment resulted in rather variable structural as well as functional data. There were no differences in the volumes of intraalveolar edema among the groups tested. However, the volume of alveolar tissue was increased in the Euro-Collins group. In conclusion, compared with Euro-Collins and Celsior + prostacyclin solutions, preservation with Celsior resulted in improved structural characteristics which in combination with improved oxygenation parameters supports the prospective advantage of Celsior in clinical organ preservation.
Fehrenbach
A
A
Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, Hannover, D-30625, Germany. afehren@gwdg.de
Wittwer
T
T
Cornelius
J
J
Ochs
M
M
Fehrenbach
H
H
Wahlers
T
T
Richter
J
J
D000818:Animals; D004187:Disaccharides / Q000494:pharmacology; D004338:Drug Combinations; D004573:Electrolytes / Q000494:pharmacology; D011464:Epoprostenol / Q000494:pharmacology; D005971:Glutamates / Q000494:pharmacology; D005978:Glutathione / Q000494:pharmacology; D006639:Histidine / Q000494:pharmacology; D006982:Hypertonic Solutions / Q000494:pharmacology; D008168:Lung / Q000473:pathology* / Q000503:physiopathology*; D008176:Lung Volume Measurements; D008297:Male; D008353:Mannitol / Q000494:pharmacology; D009926:Organ Preservation; D019188:Organ Preservation Solutions / Q000494:pharmacology*; D011650:Pulmonary Alveoli / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000473:pathology / Q000503:physiopathology
C088453:Celsior; D004187:Disaccharides; D004338:Drug Combinations; D004573:Electrolytes; C037096:Euro-Collins' solution; D005971:Glutamates; D006982:Hypertonic Solutions; D019188:Organ Preservation Solutions; D008353:Mannitol; D006639:Histidine; D011464:Epoprostenol; D005978:Glutathione